EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Marjorie G. Zauderer, Peter W. Szlosarek, Sylvestre Le Moulec, Sanjay Popat, Paul Taylor, David Planchard, Arnaud Scherpereel, Marianna Koczywas, Martin Förster, Robert B. Cameron, Tobias Peikert, Evren Kocabaş Argon, Neil R. Michaud, Attila Szántó, Jay Yang, Yingxue Chen, Vikram Kansra, Shefali Agarwal, Dean A. Fennell